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We tested whether rat and human MPO have similar antigenic determinants using 36 human MPO-
ANCA positive sera, one mouse anti-rat MPO and four mouse anti-human MPO monoclonal reagents.
Purified rat and human MPO were used in ELISA, with or without crossinhibition by preincubation
with human MPO or irrelevant antigen in the liquid phase. Only one human MPO ANCA positive
serum exhibited significant binding in rat MPO ELISA. This binding was poorly inhibited by preincu-
bation with human MPO in the liquid phase, but was conserved after adsorption of non specific anti-rat
activity in a chromatography column. Three mouse anti-human MPO IgG monoclonal antibodies did
not recognize rat MPO. Only one mouse anti-human MPO IgA monoclonal antibody bound to rat





versely, the mouse anti-rat MPO monoclonal did not bind human MPO. We have concluded that: (1)
Most human MPO-ANCA recognize antigenic determinants on human MPO which are absent on rat
MPO. Therefore, human auto-antibodies bind to epitopes which recently appeared after species evo-
lution; (2) Inversely, the mouse anti-rat MPO monoclonal do not bind human MPO. Therefore, rat MPO
epitopes have been altered during species evolution; (3) Mice injected with human MPO preferentially
develop antibodies against xeno-epitopes which are not present in rodents. Therefore, human MPO may
not be the best antigen to raise ANCA in animal models and (4) A comparison of the amino acid








Anti-neutrophil cytoplasmic antibodies (ANCA) are found in
small vessel vasculitides, namely Wegener’s granulomatosis and
microscopic polyangiitis. These autoantibodies are directed
against proteins contained in polymorphonuclear (PMN) gran-
ules and monocytes lysosomes, mainly proteinase-3 (PR-3), a
serine protease, and myeloperoxidase (MPO), an enzyme
involved in the production of reactive oxygen intermediates [1].
ANCA may not be only markers of disease activity [2], but could
play a direct role in the pathophysiology of systemic vasculitis.





, PR3 and MPO are expressed at the cell surface, and
subsequent binding of ANCA induce a respiratory burst as well as
degranulation of proteolytic enzymes [3], that can lead to lysis of
endothelial cell cultures [4].
ANCA can be generated in animal models using various strat-




 injection in Brown
Norway (BN) rats that exhibited gut vasculitis [5]. In several
other studies, BN rats were immunized with human MPO, and









sion [6], ischaemia [7], or a subnephritogenic dose of antiglomer-
ular basement membrane antibodies [8]. The lung was also
successfully targeted using similar strategies [9]. However, the rel-
evance of xeno-antigen injections to induce anti-MPO antibodies
in rats remains debated since novel antigen determinants may
have appeared during species evolution.
The aim of this study was to test the hypothesis that rat and
human MPO may exhibit different epitope profiles, using both
purified rat and human MPO, human MPO-ANCA, and mouse
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Rats were injected intraperitoneally with 30 ml of 3% protease
peptone in saline, followed by another injection of 10 ml 24 h
later. Two hours later, the peritoneal cavity was lavaged with
100 ml of normal saline.









C with a homogenizer. The homogenate was centrifuged at 200




C, and the supernatant was removed and cen-




C. The pellet containing the













, sonicated and then centri-




C. The supernatant fluid contained
granule protein [10]. The granule proteins were chromato-
graphed on an FPLC mono S cation-exchange column, HR5/5
(Pharmacia, Uppsala, Sweden). Bound proteins were eluted with
a gradient from 0·15 to 2·0 mol/l NaCl in 0·05 mol/l sodium ace-
tate buffer, pH 4·0 at a flow rate of 1 ml/minute. The peaks
between 0·6 and 0·8 mol/l NaCl contained MPO and elastase. The
combined and concentrated fractions of these peaks were applied
to a FPLC Superose 12 gel filtration column HR16/50 (Pharma-
cia). Protein was eluted with 0·05 mol/l sodium acetate buffer
pH 5·0 at a flow rate of 0·5 ml/minute and resulted in only 2
major peaks. The peak corresponding to a molecular weight of
approximately 140 kDa was identified as MPO by enzymatic









in phosphate buffered saline (PBS). After blocking with PBS con-
taining 2% bovine serum albumin (BSA, Bioatlantic, Nantes,
France), test sera were incubated either undiluted for one mon-
oclonal mouse anti-rat MPO supernatant, or diluted in PBS con-
taining 0·1% Tween for 4 purified mouse anti-human MPO









IgG concentration), 36 MPO-ANCA positive human sera and 10
negative control human sera (1 : 50). Binding was detected with
either alkaline phosphatase-conjugated anti-mouse Ig (A8438,
Sigma, St Louis, MO, USA) diluted 1 : 30 000, or alkaline phos-
phatase-conjugated anti-human IgG (A3150, Sigma) 1 : 1000,









C for one hour, with triple washes in PBS-Tween
0·1%. Positivity was defined as values greater than 3 SD over the




MPO-ANCA was determined using commercial kits according
to the manufacturer’s instructions (MK031, The binding site,
Birmingham, UK) in 36 consecutive ANCA positive samples
from 36 patients, both during active disease and at follow-up.
Mouse anti-human MPO monoclonal reagents were character-
ized by ELISA and Western blotting as previously reported,
using purified human MPO (Calbiochem, La Jolla, CA, USA)
[12]. Three IgG (1B10, 2C7, 2F2) and one IgA (1H2) mono-
clonal reagents, that recognized distinct epitopes on human
MPO [12] were used.
Mouse anti-rat MPO supernatant was incubated undiluted,
and binding was compared to seven normal mouse sera as
described for rat MPO ELISA.
 
Inhibition of human or mouse anti-MPO reagents binding to rat 
MPO with human MPO
 
Serial dilution curves were used to determine the limiting rat
MPO coating concentration in the rat MPO ELISA, that is the
concentration below which a decrease binding of mouse anti-rat
MPO antibody is observed in the assay.
Serial dilution of MPO-ANCA positive sera or mouse anti-
human MPO monoclonal that exhibited significant binding in the
rat MPO ELISA were applied in this rat MPO ELISA using lim-
iting antigen coating concentration. The limiting antibody concen-
tration was defined as the serum dilution below which a decrease
binding in this ELISA was observed. Both limiting antigen coat-
ing concentration and limiting antibody concentrations were used
for subsequent inhibition studies.
Anti-human MPO reagents were preincubated with purified








g/ml) or an irrelevant









incubation on rat MPO coated ELISA plates. Results were










 binding of test serum




 binding of control
sera.
 
Binding of human MPO-ANCA on rat MPO ELISA after 
adsorption of non-specific anti-rat activity
 
A chromatography column was filled with 1 g of CNBr activated




HCl. One ml of pooled normal rat sera was added diluted 1 : 4
in coupling buffer. Remaining sepharose active groups were




 Tris-HCl pH 8 for 2 h at room temperature.
Human MPO-ANCA positive sera were passed down the column
and the unbound fraction was collected. IgG concentrations were
checked, and binding of native and adsorbed sera were compared
at the same final IgG concentration in rat MPO ELISA.
 
Mouse IgA anti-human MPO monoclonal binding to human or 
rat MPO in the presence of jacalin
 
Jacalin is a lectin known to bind to the sugar residues of the IgA
hinge region, responsible for IgA stickiness in solid phase assays.





ml jacalin (AbCys, Paris, France) for 1 h at room temperature.




Binding of human MPO-ANCA and mouse anti-human MPO 
monoclonal to rat MPO
 





significant binding in rat MPO ELISA (3·6 SD over the mean
binding of 10 control human sera).
The three mouse IgG anti-human MPO monoclonal did not
recognize rat MPO. Only one mouse IgA anti-human MPO mon-
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normal mouse sera) (Fig. 1), with binding of the positive control
(mouse anti-rat MPO supernatant) of 137·76 SD. The avidity of
human polyclonal MPO-ANCA and mouse anti-human or rat
MPO monoclonal should not be compared since controls and spe-
cies specific reagents are different.
 
Binding of human MPO-ANCA and mouse anti-rat MPO 
monoclonal to human MPO
 


















 100 U, and was drawn during apparent
clinical remission in 1996. Patient no. 4 presented on March 1994
with pneumonia, rapidly progressive glomerulonephritis and pur-
pura. He was diagnosed as microscopic polyangiitis and treated
by steroids and cyclophosphamide boluses. He is in remission
since 1995 despite persisting MPO-ANCA activity.
The mouse anti-rat MPO monoclonal did not bind human
MPO.
 
Inhibition of binding to rat MPO by preincubation with
human MPO
 
The binding of the human MPO-ANCA positive serum to rat
MPO was poorly inhibited by preincubation with human MPO in




g/ml) (Fig. 2). The bind-
ing of the mouse IgA anti-human MPO monoclonal was only
inhibited by preincubation with high concentration of human




g/ml), suggesting that this IgA mol-
ecule may bind to rat MPO by non antigen specific sites (Fig. 2).
The binding of mouse anti-rat MPO monoclonal reagent to rat
MPO was also poorly inhibited by preincubation with human






Inhibition of mouse IgA anti-human MPO monoclonal binding 
to rat MPO by jacalin
 
Jacalin did not prevent the binding of the mouse anti-human
MPO monoclonal to rat MPO or human MPO (0%
inhibition).
 
Inhibition of human MPO-ANCA positive serum binding to rat 
MPO after adsorption of non-specific anti-rat activity
 
The binding of this human MPO-ANCA positive serum to rat
MPO was not affected by the passage through the chromatogra-




Our study show that most human MPO-ANCA and all our mouse
anti-human MPO IgG monoclonal reagents recognize antigenic
determinants on human MPO which are absent on rat MPO.
Inversely, the mouse anti-rat MPO monoclonal does not bind to
human MPO, confirming that rat MPO epitopes have been
altered during species evolution. MPO is a key enzyme involved
in the generation of powerful oxygen species, that are crucial for
the protection against attack by foreign microorganisms. This may
explain the high sequence homology of rodent (mouse) and
human peroxidases through species evolution [13]. Therefore, it is
striking that human auto-antibodies bind to epitopes which
recently appeared after evolution from low mammals to human.
The reason why tolerance to those newly appeared epitopes is less
accurate remains to be determined. Negative selection in the thy-
mus is mediated by random presentation of self epitopes. Those
newly appeared determinants may escape to the screen of the
maturing immune system.
Most epitopes recognized by anti-human MPO mice mono-
clonal reagents are not present on rat MPO. Therefore, mice
injected with human MPO preferentially develop antibodies
against xeno-epitopes which are not present in rodents. This does
not rule out the possibility that rat injected with human MPO may




Serial dilution curves of four mouse anti-human MPO monoclonal





) bound to rat MPO. None of the mouse IgG anti-












) exhibited binding to
rat MPO. The dotted line is the threshold for positivity in the assay (3 SD


















Inhibition of binding to rat MPO by preincubation with human
MPO in the liquid phase. Both limiting rat MPO coating concentration














, the only human serum exhibiting binding in the rat MPO
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shown [6,7]. However, our study points out that human MPO pre-
sents several epitopes which are not present in rodents. We there-
fore suggest that rat MPO would be a better antigen with which to
induce models of vasculitis in rats. However, certain models of
renal vasculitis in the rat appear to be induced by [14] or exacer-
bated by immunization with human MPO [6–9], and MPO/
anti-MPO complexes has not been consistently observed [10],
raising the possibility that induction of ANCA by human MPO
may have pathological consequences.
Two new strategies have been used to generate auto-anti-
bodies directed to ANCA auto-antigens. First, the tolerance to
ANCA auto-antigens was broken in BN rats by injection of syn-
genic apoptotic neutrophils [15]. However, those animals did not
exhibit signs of vasculitis. Second, anti-MPO antibodies were
raised by injection of mouse MPO to MPO deficient mice, and
adoptive transfer of their splenocytes in recombinase activating
gene 2 deficient mice (RAG-/–) led to crescentic glomerulone-
phritis with immune complex deposition and MPO-ANCA
activity [16]. Furthermore, susceptible strains of mice may
spontaneously develop crescentic glomerulonephritis in the pres-
ence of ANCA, and this model has already been used to compare
new therapeutic strategies [17]. However, several additional
autoantibodies are detected in these mice, and not all of them
develop glomerulonephritis [18]. The search for an animal model
that could be manipulated to develop systemic vasculitis with
antibodies directed to neutrophil cytoplasmic auto-antigens
remains a challenge.
The inability to induce anti-MPO-mediated vasculitis in
rodents based on the passive transfer of human anti-MPO anti-
bodies has been in part attributed to the lack of reactivity of anti-
human MPO to the rodent antigen. This contention has however,
never been verified experimentally. In fact, the high degree of
homology between the human and rodent molecules [13] would
predict some cross-reactivity of the antibodies. The lack of cross-
reativity of anti-human MPO to the rat antigen, despite the high
degree of homology between the two molecules suggests that
these antibodies are directed against epitopes that are not shared.
A comparison of the amino acid sequences of the two homo-
logueous molecules may help elucidate the major antigenic
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